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A
  Does red wine reduce 
cardiovascular risks? 
 yes. Moderate daily red wine con-
 sumption decreases cardiovascular 
risk compared with either abstinence or 
heavy and binge drinking (strength of rec-
ommendation [SOR]: B, meta-analysis of 
prospective cohort and case-control stud-
ies); however, not enough evidence exists 
to determine whether wine reduces car-
diovascular risk more than other alcoholic 
beverages. 
A high dietary intake of fl avonoids, con-
tained in red wine and other food products, 
correlates with decreased mortality from 
coronary heart disease (CHD) (SOR: B, 
meta-analysis of prospective cohort studies).
Heavy alcohol drinking is associated 
with an increased risk of stroke, but data are 
lacking for low and moderate levels of wine 
consumption. (SOR: B, meta-analysis of pro-
spective cohort and case-control studies).
Evidence summary
A 2-part meta-analysis of 26 studies enrolling 
men, women, or both, showed a signifi cant in-
verse association between red wine consump-
tion and fatal and nonfatal cardiovascular 
events. Th e fi rst part, encompassing 13 stud-
ies (5 prospective cohort and 8 case-control 
studies with a total of 209,418 participants), 
compared moderate wine drinkers with non-
drinkers and heavy or binge drinkers. Moderate 
drinkers consumed an average of 1 to 2 drinks 
per day.1 Th is meta-analysis, and other studies 
described in this summary, defi ned a drink as 
130 mL of wine with 12% ethanol content. 
For all 13 studies combined, moderate 
wine drinking signifi cantly reduced cardio-
vascular events at 2 to 24 years of follow-up 
compared with no drinking and heavy drinking 
(relative risk [RR]=0.68; 95% confi dence inter-
val [CI], 0.59-0.77). A pool of the 7 studies that 
enrolled both male and female participants 
also found that wine drinking signifi cantly re-
duced cardiovascular events (RR=0.53; 95% CI, 
0.42-0.68). However, pooled results from the 
6 studies with exclusively male participants 
found no diff erence in cardiovascular events 
with wine consumption (RR=0.87; 95% CI, 
0.68-1.12). Beer drinking, which was also eval-
uated, produced statistically signifi cant risk 
reductions in studies of both men and women; 
the eff ect was smaller in men-only studies.1 
CV risk decreases with increased 
wine intake—to a point
Th e second part of the meta-analysis, 7 pro-
spective cohort and 3 case-control studies 
with a total of 176,042 participants, found an 
apparent J-shaped dose-response relation-
ship between wine intake and cardiovascular 
risk reduction. Daily consumption ranged 
from 0 to 1738 mL, although most participants 
had 0 to 3 drinks (390 mL) per day. Data from 
the 7 prospective studies illustrated a progres-
sive decrease in cardiovascular risk as wine 
intake increased to 150 mL per day. Con-
suming larger amounts of wine (as much as 
750 mL per day) showed a trend toward fur-
ther cardiovascular risk reduction, but the 
trend wasn’t statistically signifi cant.1 
High fl avonoid intake is associated 
with lower CHD mortality
A meta-analysis of 7 prospective cohort stud-
ies including 105,000 men and women 30 to 84 
years of age indicated that a high dietary intake 
of fl avonoids (present in larger amounts in red 
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wine, chocolate, tea, and other foods) corre-
lated with reduced CHD mortality. Participants 
whose fl avonoid consumption was in the high-
est third had signifi cantly less CHD mortality 
than participants in the bottom third (RR=0.80; 
95% CI, 0.69-0.93; P<.001). Th e meta-analysis 
couldn’t determine whether the fl avonoid con-
tent of red wine confers additional cardiovas-
cular benefi t beyond that of alcohol alone.2
Heavy drinking increases risk of stroke
A meta-analysis of 41 studies (3 cross-
sectional, 21 case-control, and 17 cohort stud-
ies) enrolling both men and women, correlat-
ed heavy alcohol drinking (>4 drinks per day, 
on average) with increased risk of stroke. Sev-
en of 9 retrospective studies associated heavy 
drinking with an increase in risk as great as 
6.5-fold for hemorrhagic and ischemic stroke, 
but found no consistent association between 
stroke and light-to-moderate drinking. Evi-
dence was insuffi  cient to evaluate stroke risks 
specifi c to low or moderate wine intake.3
Recommendations 
Th e US Department of Health and Human Ser-
vices’ Dietary Guidelines for Americans 2005
state that moderate daily wine intake in adults 
(5 oz for women and 10 oz for men) is associ-
ated with the lowest all-cause mortality and 
CHD. Th e guidelines warn against drinking 
by people who are susceptible to the harmful 
eff ects of alcohol and participants in activities 
that require attention, skill, or coordination.4
Th e American Heart Association states 
that moderate alcohol consumption (1-2 
drinks daily) may be considered safe in the ab-
sence of contraindications, and recommends 
consulting a physician fi rst.5
Th e National Institute on Alcohol Abuse 
and Alcoholism of the National Institutes of 
Health says that moderate drinkers are less 
likely to die from coronary artery disease than 
are people who don’t drink any alcohol or who 
drink more alcohol. It recommends against 
nondrinkers starting to drink solely to benefi t 
their hearts, however.6 JFP
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Special issue on diabetes
As the prevalence of type 2 diabetes mellitus (T2DM) rises, primary care 
physicians must be prepared to manage this disease. In this supplement, 
5 key topics related to T2DM are discussed—obesity, postprandial glucose, 
diabetic peripheral neuropathic pain, dyslipidemia, and the incretins. 
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